Cargando…
Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce...
Autores principales: | Kochanowska, Anna, Rusztyn, Przemysław, Szczerkowska, Karolina, Surma, Stanisław, Gąsecka, Aleksandra, Jaguszewski, Miłosz J., Szarpak, Łukasz, Filipiak, Krzysztof J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380892/ https://www.ncbi.nlm.nih.gov/pubmed/37504524 http://dx.doi.org/10.3390/jcdd10070268 |
Ejemplares similares
-
Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis
por: Jaguszewski, Milosz J., et al.
Publicado: (2021) -
Nanoparticles: a breakthrough in COVID-19 prevention, diagnosis and treatment
por: Skwarek, Aleksandra, et al.
Publicado: (2021) -
Correlation between takotsubo cardiomyopathy and SARS-CoV-2 infection
por: Szarpak, Lukasz, et al.
Publicado: (2021) -
Effect of Coronary Artery Disease on COVID-19—Prognosis and Risk Assessment: A Systematic Review and Meta-Analysis
por: Szarpak, Lukasz, et al.
Publicado: (2022) -
Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)